Skip to main content
Erschienen in: DNP - Der Neurologe & Psychiater 6/2015

29.05.2015 | Fortbildung

Unerwünschte Arzneimittelwirkungen

Emotionale Verflachung unter antidepressiver Therapie

verfasst von: PD Dr. med. Michael Landgrebe, Prof. Dr. med. Göran Hajak, MBA

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Antidepressiva stellen neben der Psychotherapie eine wesentliche Säule der Depressionsbehandlung dar. Die Verträglichkeit ist sehr wichtig, da Nebenwirkungen der häufigste Grund sind, warum Medikamente wieder abgesetzt werden. So kristallisiert sich zunehmend heraus, dass bestimmte Antidepressiva auch unerwünschte Nebenwirkungen auf das emotionale Erleben des Patienten haben können, die in der Praxis häufig übersehen werden.
Literatur
1.
Zurück zum Zitat Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Sep;21(9):655–79.CrossRefPubMed Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Sep;21(9):655–79.CrossRefPubMed
2.
Zurück zum Zitat Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Oct;21(10):718–79.CrossRefPubMed Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Oct;21(10):718–79.CrossRefPubMed
3.
Zurück zum Zitat DGPPN BK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Kurzfassung. Berlin, Düsseldorf: DGPPN, ÄZQ, AWMF; 2009. DGPPN BK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Kurzfassung. Berlin, Düsseldorf: DGPPN, ÄZQ, AWMF; 2009.
4.
Zurück zum Zitat Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009 Feb 28;373(9665):746–58.CrossRefPubMed Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009 Feb 28;373(9665):746–58.CrossRefPubMed
5.
Zurück zum Zitat Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010 Oct;71(10):1259–72.CrossRefPubMed Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010 Oct;71(10):1259–72.CrossRefPubMed
6.
Zurück zum Zitat Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009 Jun;29(3):259–66.CrossRefPubMed Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009 Jun;29(3):259–66.CrossRefPubMed
7.
Zurück zum Zitat Lin EH, Von Korff M, Katon W, Bush T, Simon GE, Walker E, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995 Jan;33(1):67–74.CrossRefPubMed Lin EH, Von Korff M, Katon W, Bush T, Simon GE, Walker E, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995 Jan;33(1):67–74.CrossRefPubMed
8.
Zurück zum Zitat Fritze J. Psychopharmaka-Verordnungen: Ergebnisse und Kommentare zum Arzneiverordnungsreport 2011. Psychopharmakotherapie. 2011;18:245–56. Fritze J. Psychopharmaka-Verordnungen: Ergebnisse und Kommentare zum Arzneiverordnungsreport 2011. Psychopharmakotherapie. 2011;18:245–56.
9.
Zurück zum Zitat Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009 Sep;195(3):211–7.CrossRefPubMed Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009 Sep;195(3):211–7.CrossRefPubMed
10.
Zurück zum Zitat Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol. 1990 Oct;10(5):343–5.CrossRefPubMed Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol. 1990 Oct;10(5):343–5.CrossRefPubMed
11.
Zurück zum Zitat Hoehn-Saric R, Pearlson GD, Harris GJ, Machlin SR, Camargo EE. Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients. AmJPsychiatry. 1991;148:1243–5. Hoehn-Saric R, Pearlson GD, Harris GJ, Machlin SR, Camargo EE. Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients. AmJPsychiatry. 1991;148:1243–5.
12.
Zurück zum Zitat Oleshansky MA, Labbate LA. Inability to cry during SRI treatment. J Clin Psychiatry. 1996 Dec;57(12):593.CrossRefPubMed Oleshansky MA, Labbate LA. Inability to cry during SRI treatment. J Clin Psychiatry. 1996 Dec;57(12):593.CrossRefPubMed
13.
Zurück zum Zitat Opbroek A, Delgado PL, Laukes C, McGahuey C, Katsanis J, Moreno FA, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol. 2002 Jun;5(2):147–51.CrossRefPubMed Opbroek A, Delgado PL, Laukes C, McGahuey C, Katsanis J, Moreno FA, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol. 2002 Jun;5(2):147–51.CrossRefPubMed
14.
Zurück zum Zitat Garland EJ, Baerg EA. Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol. 2001 Summer;11(2):181–6.CrossRefPubMed Garland EJ, Baerg EA. Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol. 2001 Summer;11(2):181–6.CrossRefPubMed
15.
Zurück zum Zitat Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004 Jul;161(7):1256–63.CrossRefPubMed Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004 Jul;161(7):1256–63.CrossRefPubMed
16.
Zurück zum Zitat Harmer CJ, O'Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009 Oct;166(10):1178–84.CrossRefPubMed Harmer CJ, O'Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009 Oct;166(10):1178–84.CrossRefPubMed
17.
Zurück zum Zitat Harmer CJ, de Bodinat C, Dawson GR, Dourish CT, Waldenmaier L, Adams S, et al. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol. 2011 Sep;25(9):1159–67.CrossRefPubMed Harmer CJ, de Bodinat C, Dawson GR, Dourish CT, Waldenmaier L, Adams S, et al. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol. 2011 Sep;25(9):1159–67.CrossRefPubMed
18.
Zurück zum Zitat Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009 Aug;195(2):102–8.CrossRefPubMed Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009 Aug;195(2):102–8.CrossRefPubMed
19.
Zurück zum Zitat Pringle A, Browning M, Cowen PJ, Harmer CJ. A cognitive neuropsychological model of antidepressant drug action. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1586–92.CrossRefPubMed Pringle A, Browning M, Cowen PJ, Harmer CJ. A cognitive neuropsychological model of antidepressant drug action. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1586–92.CrossRefPubMed
20.
Zurück zum Zitat Corruble E, de Bodinat C, Belaidi C, Goodwin GM. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013 Nov;16(10):2219–34.CrossRefPubMed Corruble E, de Bodinat C, Belaidi C, Goodwin GM. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013 Nov;16(10):2219–34.CrossRefPubMed
21.
Zurück zum Zitat Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. JPsychopharmacol. 2007;21(5):461–71.CrossRef Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. JPsychopharmacol. 2007;21(5):461–71.CrossRef
22.
Zurück zum Zitat Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 Jan;163(1):28–40.CrossRefPubMed Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 Jan;163(1):28–40.CrossRefPubMed
23.
Zurück zum Zitat Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010 Jan;40(1):41–50.CrossRefPubMed Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010 Jan;40(1):41–50.CrossRefPubMed
24.
Zurück zum Zitat Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69 Suppl E1:4–7.PubMed Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69 Suppl E1:4–7.PubMed
Metadaten
Titel
Unerwünschte Arzneimittelwirkungen
Emotionale Verflachung unter antidepressiver Therapie
verfasst von
PD Dr. med. Michael Landgrebe
Prof. Dr. med. Göran Hajak, MBA
Publikationsdatum
29.05.2015
Verlag
Urban & Vogel
Erschienen in
DNP – Die Neurologie & Psychiatrie / Ausgabe 6/2015
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI
https://doi.org/10.1007/s15202-015-0817-2

Weitere Artikel der Ausgabe 6/2015

DNP - Der Neurologe & Psychiater 6/2015 Zur Ausgabe